To understand efficacy benefit of transient higher concentration of CAR T cell in pleural space following intrapleural injection, a pleural tumor model was added to the base model to describe literature reported mesothelin-targeting CAR T cellular kinetics and the tumor growth inhibition profiles following i.v. and intrapleural delivery [12] (Fig. 5). The gene discussed is MSLN; the disease is pleural neoplasm.